In a recent Honyman Gillespie Lecture 
In a recent Honyman Gillespie Lecture, Professor Davidson gave an account of the physiological and clinical effects of the adrenocorticotropic hormone of the pituitary gland and the steroid hormones of the adrenal cortex. He reviewed recent research in this field, and described the remarkable effects of these hormones in rheumatoid arthritis, rheumatic fever, gout and other diseases of the collagen group.
The purpose of the present communication is to describe the results of clinical trials of ACTH carried out in Edinburgh during the last four months. It was obvious from the outset that supplies of the hormone would be limited and that it would not be possible to use the high doses and prolonged courses given in American Clinics. It was felt, however, that a very useful purpose might be served by trials on a much more limited scale, which would provide first-hand experience of the clinical effects of ACTH, and it was also our hope that we might be fortunate enough to observe some clinical or metabolic result which had not as yet been fully described by workers in America. Admittedly our hopes were modest, because perusal of the ever-increasing number of papers covering the clinical, biochemical and metabolic effects of ACTH seemed to leave little scope for original work with the limited facilities available. However, the most generous support was received from all departments to whom application was made for advice or help.
The clinical side of these trials represents the combined effort of a group of physicians working in the Department of Medicine and the Unit for Rheumatic Diseases in the Northern General Hospital.
In the time available it will only be possible to give a brief outline of the work done since supplies of ACTH were received four months ago.
Certain lines of investigation are now being followed which may or may not shed some new light on the action of ACTH in rheumatic diseases, but much more work will have to be done before any conclusions can be reached.
First, the organisation of the trials will be described along with some of the methods of clinical assessment which have been evolved. It must be borne in mind that even four months ago very much less was known about the action of ACTH than is the case now, and this must be the excuse for certain errors of judgment and the failure to record information which experience has shown might have proved valuable.
A Honyman Gillespie Lecture delivered on 18th May 1950. In view of the results obtained by Hench and his A striking feature in this patient was the extreme degree of muscular stiffness. Without Urinary 17-ketosteroids were more than doubled during ACTH, and there was a rise in the uric acid/creatinine ratio (Fig. 6) .
In another patient the response to ACTH was more clear-cut. Progesterone in this case did not appear to influence the electrolyte pattern in the urine. The uric acid/creatinine ratio rose more sharply (Fig-7 (Fig. 9) .
This first patient conformed in every respect to the pattern of immediate clinical response described by Hench and Hematology (Fig. 14 Fig. 19 . Fig. 19 . Fig. 20 . Fig. 20 . Fig. 2i . Fig. 2i . Fig. 22 . Fig. 22 . Fig. 19 shows her appearance before ACTH. Fig. 20 shows the marked rounding of her face, which appeared on the fifth day of ACTH.
Generalised oedema developed rapidly, breathlessness returned, diffuse crepitations were heard as high as the apices of both lungs, there was a sharp rise in blood pressure, albuminuria increased, and she became cyanosed.
The picture was that of acute left ventricular failure. Fig. 21 shows the X-ray appearance of the chest before ACTH. Fig. 22 shows the appearance on the fifth day of ACTH. ACTH was stopped, as it was obvious that she had suddenly begun to retain fluid and that the increased load had precipitated cardiac failure. She was digitalised, and put on a salt-free diet. A moderate diuresis followed, and the signs of congestive failure rapidly diminished.
Joint pain returned and was more severe than on any previous occasion. Albuminuria decreased, and blood pressure^ fell slightly, and her general condition improved. This sudden emergency illustrates the dangers of AC 1 H in the presence of cardiac and renal disease.
On 2.1.50 ACTH was restarted in small doses?5 mg. 8-hourly. This was continued for 3 days, when rounding of the face returned. The dose was reduced to xo mg. daily, and continued at this lev el for 10 days. There was a slow improvement in her general condition, a fall in blood sedimentation rate and a rise in haemoglobin. AC I H was stopped, and she was put on glucose and peanut oil drip by stomach tube for 5 days. There was a fall in blood pressure, and ACTH was resumed at 20 mg. daily for 5 days. Following this last course, there was a sudden and spectacular rise in the eosinophils , and from this time on there was a steady improvement in her condition?blood pressure and pulse rate fell steadily, albuminuria decreased. plasma proteins tended to return to a normal pattern (Fig. 18) 1 here were no signs of remission until she received ACTH. Only four doses of 25 mg. were given?a total of 100 mg. (Fig. 29) . Capillary resistance arose, and all signs of haemorrhage disappeared. The remission has continued up to date, although platelets and capillary resistance have returned to subnormal levels.
A single dose of 25 mg. of ACTH was given to a patient who had her spleen removed on account of thrombocytopenic purpura three years ago. The rise in capillary resistance in this instance was extremely rapid (Fig. 30) 
